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Human mesenchymal stem cells (hMSCs) have self-renewal and differentiation capabilities but the
regulatory mechanisms of MSC fate determination remain poorly understood. Here, we aimed to
identify microRNAs enriched in hMSCs that modulate differentiation commitments. Microarray
analysis revealed that miR-140-5p is commonly enriched in undifferentiated hMSCs from various
tissue sources. Moreover, bioinformatic analysis and luciferase reporter assay validated that
miR-140-5p directly represses bone morphogenic protein 2 (BMP2). Furthermore, blocking miR-
140-5p in hMSCs increased the expression of BMP signaling components and critical regulators of
osteogenic differentiation. We propose that miR-140-5p functionally inhibits osteogenic lineage
commitment in undifferentiated hMSCs.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human mesenchymal stem cells (hMSCs) are multipotent stro-
mal cells that have a capability for self-renewal and differentiation
[1]. Due to their therapeutic effects, MSCs have been the focus of
intensive efforts during recent decades aimed at developing stem
cell-based therapies for a wide range of human diseases [2].
Despite the advances made since their discovery, the regulatory
mechanisms of MSC fate determination remain poorly understood.
MicroRNAs (miRNAs) are 22-nucleotide small non-coding
RNAs that regulate target genes by both translational inhibition
and mRNA destabilization [3]. Numerous studies suggest that
miRNAs are key players in many, if not most, fundamental cellularprocesses and their altered expression may underlie diverse
human diseases [4].
There is growing evidence for functional roles of miRNAs in
hMSCs. For example, subsets of miRNAs have been identiﬁed as
regulators of osteogenic differentiation [5–10] and adipogenic dif-
ferentiation [11–13]. Interestingly, more recent genome-wide
analyses have identiﬁed that miR-146a-5p and miR-335 regulate
hMSC cell proliferation and migration [14,15]. However, miRNAs
essential for the regulation of stem cell maintenance and differen-
tiation determination have mainly been studied in embryonic stem
cells [16,17].
In our current study, we identiﬁed miRNAs, namely miR-140
(both miR-140-5p and miR-140-3p), that are enriched in hMSCs
from various human tissues, including adipose, bone marrow,
and umbilical cord, compared with ﬁbroblasts, which are a more
differentiated mesenchymal cell type. We then demonstrated
using target prediction and luciferase reporter assays that bone
morphogenic protein 2 (BMP2) is a direct target of miR-140-5p.
Furthermore, the inhibition of miR-140-5p expression in hMSCs
upregulates BMP2 and its receptors including bone morphogenic
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expression of Smad5, an intracellular BMP2 coreceptor, also
increased. Interestingly, critical regulators of osteogenic differenti-
ation such as runt-related transcription factor 2 (RUNX2), alkaline
phosphatase (ALP), osteocalcin (OCN), and osteopontin (OPN) are
expressed in undifferentiated hMSCs upon miR-140-5p inhibition.
Furthermore, in the ALP staining assay, the ALP level was increased
upon miR-140-5p inhibition, indicating the formation of osteo-
blasts. Taken together, our data indicate that miR-140-5p represses
osteogenic lineage commitment in undifferentiated hMSCs at least
in part by negatively regulating BMP2-mediated signaling
pathway.
2. Materials and methods
2.1. Cell culture
This study was performed with the approval and in accordance
with the guidelines of the Institutional Review Board of the Asan
Medical Center. hMSCs from various sources were isolated from
donors who provided informed consent. hMSCs were harvested
and cultured as previously described [18,19] and characterized
for cell surface markers. Human skin and lung ﬁbroblasts were
obtained from Medipost (Seoul, Korea). All cell lines were cultured
in Dulbecco’s modiﬁed Eagle’s medium (Gibco) supplemented with
10% heat-inactivated fetal bovine serum (Gibco), 100 units/ml
penicillin, and 100 lg/ml streptomycin (Gibco) in 5% CO2 in a
humidiﬁed incubator at 37 C. All hMSC experiments were per-
formed at passage 3–6. For osteogenic differentiation, cells were
cultured using StemPro osteogenesis differentiation kit (Gibco)
according to the manufacturer’s instructions.
2.2. miRNA microarray and data analysis
miRNA microarray and data analyses were carried out as previ-
ously described [20] using Agilent Human microRNA microarray
release 16.0 (G4870A; Agilent Technologies) for proﬁling. Brieﬂy,
total RNA was isolated using Trizol (Life Technologies) and
100 ng per sample was hybridized to the microarray. We compared
the expression proﬁles of two different donors per hMSC to that of
ﬁbroblasts. miRNA labeling, hybridization, and washing were
performed according to the manufacturer’s instructions. Global
normalization was performed by using all of the data, and differen-
tially expressed miRNAs were then identiﬁed by one-way ANOVA
(P < 0.05). Thirty-six differentially expressed miRNAs were selected
for clustering analysis. Unsupervised hierarchical clustering was
performed with average linkage and a heat map was generated
in MeV (MultiExperiment Viewer, Boston, MA).
2.3. Target prediction and functional analysis
Conserved target genes of miR-140-5p and miR-140-3p were
identiﬁed using both TargeScan 6.0 and Ingenuity Pathway Analy-
sis (IPA) software (Qiagen). A conﬁdence level ﬁlter was applied for
the selection of experimentally observed and/or highly predicted
targets in IPA software. The selected lists of genes were then used
for core analysis including networks, disease functions, biological
functions and canonical pathways.
2.4. Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was isolated from cultured cells using either Trizol
reagent (Life Technologies) or a miRVana miRNA isolation kit (Life
Technologies) according to the manufacturer’s protocol. For mRNA
ampliﬁcation, reverse transcriptase reactions were performed with
random hexamers and SuperScript III reverse transcriptase (LifeTechnologies), and quantitative PCR was done on a 7900 Real-Time
PCR system using Power SYBR Green PCR master mix (Applied
Biosystems). The primers used in the qRT-PCR can be seen in
Supplementary Table 1. For qRT-PCR of miRNAs, miRNAs were ﬁrst
reverse transcribed using a miScript II RT kit and their expression
was then quantiﬁed using a miScript SYBR Green PCR kit (Qiagen)
according to the manufacturer’s protocol. SNORD68 or RNU6-2 was
used as an endogenous normalization control for miRNAs while
GAPDH was used as an mRNA control. Each reaction was per-
formed at least in triplicate and repeated in at least three different
donor samples.
2.5. Luciferase reporter assays
To construct a luciferase reporter for wild-type bmp2 30 UTR, we
cloned this UTR sequence from the genomic DNA of hMSCs by PCR.
PCR products were subcloned into the NotI and XhoI sites in a
psiCHECKTM-2 vector (Promega). A mutant bmp2 30 UTR was gener-
ated by site-directed mutagenesis using Phusion™ High-Fidelity
DNA Polymerase (Thermo Scientiﬁc) according to the manufac-
turer’s protocol. All constructs were conﬁrmed by sequence
analysis. The sequences of the primers are listed in Supplementary
Table 2. For transfection, 4  104 293T cells were plated in com-
plete medium in a 24-well plate. The next day, the cells were trans-
fected with 50 nM of miR-140-5p mimics or negative control
mimics (Thermo Fischer) using Dharmafect1 (Thermo Scientiﬁc)
following the manufacturer’s protocol. Simultaneously, the cells
were transfected with luciferase constructs at a concentration of
100 ng per well using FUGENE 6 (Roche) transfection reagent
according to the manufacturer’s guidelines. Cells were harvested
16 h after transfection in cell lysis buffer and then assayed for lucif-
erase activity using a Dual-Luciferase Reporter Assay System (Pro-
mega) on a luminometer following the manufacturer’s protocol.
Transfection of each construct was performed in triplicate in each
assay and the ratios of Renilla luciferase readings to ﬁreﬂy lucifer-
ase readings were averaged for each experiment.
2.6. Cell transfection
hMSCs were plated at a concentration of 6–7  104 in complete
medium in 6-well plates. The next day, either 50 nM of miR-
CURYLNA™ Inhibitors (Exiqon) or 10 nM of mimics (Thermo
Fischer) were transfected into the cells with DharmaFECT1
(Thermo Scientiﬁc) according to the manufacturer’s instructions.
At 48 h post-transfection, total RNA was isolated using a miRVana
miRNA isolation kit (Life Technologies) according to the manufac-
turer’s protocol and used for miRNA and mRNA qRT-PCR analysis.
2.7. Western blotting
Cells were lysed in RIPA buffer (Biosesang) containing Halt™
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientiﬁc)
at 4 C. Proteins were separated by 10% SDS–PAGE, transferred to
a polyvinylidenediﬂuoride membrane (Millipore), and probed with
anti-BMP2 (Abcam), anti-phospho-SMAD1/5 (Cell signaling), anti-
SMAD5 (Cell signaling), anti-BMPR2 (Cell signaling), anti-a-tubulin
(Sigma) and anti-GAPDH (Santa Cruz) antibodies. GAPDH or a-
tubulin was used as a loading control. Images were obtained on a
chemiluminescent image analyzer (LAS-4000 mini; Fujiﬁlm) and
quantiﬁed by ImageJ software (NIH).
2.8. Alkaline phosphatase (ALP) staining
The formation of osteoblasts was assessed by measuring the
levels of ALP staining using Leukocyte Alkaline Phosphatase kit
(Sigma). Brieﬂy, hMSCs were plated at a concentration of 1  104
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transfected with either 50 nM of miRCURYLNA™ Inhibitors
(Exiqon) or 10 nM of mimics (Thermo Fischer) and incubated for
24 h and then treated with or without 100 ng/ml recombinant
human BMP2 (R&D system). In vitro osteogenic differentiation
was then carried out using StemPro osteogenesis differentiation
kit (Gibco) according to the manufacturer’s protocol. At day 7 post
osteogenic differentiation, cells were rinsed with cold DPBS and
ﬁxed in 4% paraformaldehyde for 30 min at 25 C. The cell layer
was subsequently washed three times with cold DPBS and then
once with deionized water. Next, the cells were incubated in
FRV-alkaline solution for 20 min at 37 C and washed with deion-
ized water.
3. Results
3.1. miR-140 is enriched in undifferentiated hMSCs
We hypothesized that the key miRNAs of hMSC required for
self-renewal and differentiation fate determination would speciﬁ-
cally be found in undifferentiated stem cells rather than in ﬁbro-
blasts, which are a more differentiated mesenchymal cell type.
We therefore compared the genome-wide miRNA expression pat-
terns of undifferentiated human adipose-derived stem cells (ADS-
Cs), bone-marrow-derived stem cells (BMSCs), and umbilical
cord-derived stem cells (UCSCs) versus ﬁbroblasts using miRNA
microarrays (Fig. 1A and Supplementary Table 3). Among 1347
probes tested, 36 miRNAs showed more than 2-fold differences
in their expression levels between at least one hMSC type and
ﬁbroblasts (P < 0.05). Among these differentially expressed miR-
NAs, miR-140-5p and miR-140-3p were commonly enriched in
all three hMSC types from different tissue sources (Fig. 1B, asterisk
in the Venn diagrams). We then validated these microarray results
using real-time PCR to monitor the expression of miR-140-5p and
miR-140-3p in expanded pools of hMSCs from at least three to nine
different donors per sample. Consistent with the array data, bothFig. 1. miR-140 is enriched in undifferentiated hMSCs. (A) Heat map of miRNAs that are
green denotes downregulated miRNAs. (B) Venn diagram of the miRNAs differentially e
asterisk denotes the overlapping of two upregulated miRNAs in all hMSC cell types. The
validation of the miR-140-5p and miR-140-3p expression levels in hMSCs relative to
(⁄P < 0.01; ⁄⁄P < 0.001). The number of independent donor samples tested (n) is indicate
hBMSCs, hUCSCs, and ﬁbroblasts.miRNAs were more enriched in all three hMSC types than in ﬁbro-
blasts (Fig. 1C). Interestingly, cluster analysis using the Euclidean
distance of hADSCs, hBMSCs, and hUCSCs showed that the miRNA
expression proﬁles of hADSCs and hBMSCs were more similar to
each other than to hUCSCs (Fig. 1D).
3.2. Predictive target genes for miR-140-5p are involved in the
intrinsic functions of MSCs
To understand the regulatory functions of miR-140-5p and miR-
140-3p, we set out to determine their mRNA targets. A bioinfor-
matic analysis using both TargetScan 6.0 [21] and the Ingenuity
Pathway Analysis (IPA, http://www.ingenuity.com/) softwares
identiﬁed 377 and 114 high conﬁdence target genes for miR-140-
5p and miR-140-3p, respectively. We then carried out function
and network analysis using these selected target genes. Intrigu-
ingly, predicted target genes for both miRNAs showed enrichment
of functions related to cellular assembly and organization, cellular
function and maintenance and cell morphology. Since target genes
for miR-140-5p were more signiﬁcantly enriched for functions rel-
evant to the proliferation and/or differentiation of MSCs (Table 1),
we therefore focused on miR-140-5p in our further investigations.
3.3. miR-140-5p directly represses BMP2 expression in hMSCs
One of the targets of miR-140-5p identiﬁed in our screen was
BMP2, a potent inducer of osteogenic differentiation. We ﬁrst mon-
itored the endogenous expression levels of bmp2 in hMSCs and
found that the endogenous bmp2 transcript levels were
signiﬁcantly downregulated in all types of hMSCs compared with
ﬁbroblasts (Fig. 2A). Next, we monitored the expression levels of
miR-140-5p during the osteogenic differentiation. Notably, under
osteogenic differentiation condition, the miR-140-5-p level was
dramatically decreased during the initial steps of differentiation
(Fig. 2B, left). Furthermore, the bmp2 transcript level was drasti-
cally increased at day 2 of osteogenic differentiation (Fig. 2B, right),enriched in hMSCs compared with human ﬁbroblasts. Red denotes upregulated and
xpressed in each hMSC from various tissue sources compared with ﬁbroblasts. The
fold changes detected by microarray are denoted in the table. (C) Real-time RT-PCR
ﬁbroblasts. Error bars denote the standard error of the mean of 10 experiments
d on the x axis. (D) Dendrogram of the differentially expressed miRNAs of hADSCs,
Table 1
Principal diseases and molecular and cellular functions associated with the most
highly conserved 337 target genes of miR-140-5p (*).
Biological functions P value No. of
molecules
Cellular development 1.19E-07-6.01E-03 114
Differentiation of cells 1.19E-07 80
Proliferation of embryonic cells 4.42E-07 19
Development of osteoblasts 2.28E-06 7
Cellular growth and proliferation 4.42E-07-4.80E-03 120
Proliferation of cells 3.34E-05 118
Proliferation of connective tissue cells 2.60E-04 27
Proliferation of tumor cell lines 1.14E-03 53
Connective tissue development and
function
6.00E-09-4.78E-03 66
Abnormal morphology of skull 6.00E-09 21
Differentiation of stromal cells 2.19E-05 6
Mineralization of bone 3.45E-04 10
Embryonic development 6.00E-09-5.52E-03 110
Abnormal morphology of bone 2.13E-07 29
Formation of embryonic tissue 1.35E-06 21
Development of body axis 1.25E-05 42
⁄ These data were generated using IPA software.
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in the miR-140-5p level. Interestingly, during the later phase of
osteogenic differentiation, we observed increased expression levels
of miR-140-5p (Supplementary Fig. 1). Considering its well-
established roles as a cartilage-speciﬁc miRNA, the high levels of
miR-140-5p at later osteogenic development were not surprising.
Taken together, we concluded that the level of the endogenous
miR-140-5p was inversely correlated with that of bmp2 and tightly
regulated during osteogenic differentiation in hMSCs. WeFig. 2. miR-140-5p directly represses bmp2 expression. (A) Real-time RT-PCR analysis o
bars denote the standard error of the mean of 8 experiments (⁄P < 0.001). The number o
miR-140-5p and bmp2 at indicated time points during the initial steps of osteogenic differ
experiments (⁄P < 0.05; ⁄⁄P < 0.005). (C) Schematic of the miR-140-5p target site within th
mutant (Mut) 30 UTR regions of bmp2 showing complementary pairing. The two mutate
293T cells were cotransfected with luciferase reporters carrying either the wild-type bm
mimic) or miR-140-5p mimic. Error bars denote the standard error of the mean of 3 exspeculated that this negative correlation between the endogenous
miR-140-5p and bmp2 levels in hMSCs might be common to all
proliferating mesenchymal stem cell types.
Since miRNAs function through their binding to the 30 untrans-
lated region (UTR) of their target mRNAs [22,23], we constructed a
luciferase reporter in which the 30 UTR of bmp2 was cloned down-
stream of the Renilla luciferase reporter (Fig. 2C). To conﬁrm that
BMP2 is a direct target of miR-140-5p, we cotransfected miR-
140-5p mimics with the luciferase reporters in 293T cells. Consis-
tent with the ﬁndings of a previous report [24], the overexpression
of miR-140-5p inhibited luciferase expression by about 40%,
whereas the mock transfection and cotransfection of a negative
control mimic had no such inhibitory effect (Fig. 2D, black bars;
P = 0.0043). Furthermore, a mutation of the miR-140-5p binding
sites in the seed sequence signiﬁcantly diminished this repression,
i.e. the luciferase reporter expression was at control levels (Fig. 2D,
white bars).
3.4. miR-140-5p inhibition in hMSCs alters the expression of BMP2 and
BMP signaling molecules
To determine the functions of miR-140-5p in hMSCs, we trans-
fected these cells with locked nucleic acid (LNA) miRNA inhibitors.
Subsequent qRT-PCR analysis revealed a greater than 90% reduc-
tion in the miR-140-5p levels (Fig. 3A). Blocking miR-140-5p using
LNA-miR-140-5p caused a signiﬁcant induction of bmp2 at RNA
level, which did not occur upon transfection with a negative con-
trol miRNA inhibitor (LNA-NC) (Fig. 3B). Western blot analysis of
BMP2 demonstrated that its protein levels were also increased in
hMSCs upon inhibition of miR-140-5p expression (Fig. 3C, left).
Quantiﬁcation of these immunoblotting signals from three inde-
pendent experiments conﬁrmed the upregulation of BMP2 protein
levels in LNA-miR-140-5p-treated hMSCs (Fig. 3C, right).f bmp2 transcript levels in undifferentiated hMSCs compared with ﬁbroblasts. Error
f independent samples tested (n) is indicated on the x axis. (B) Expression levels of
entiation. Error bars denote the standard error of the mean of at least 3 independent
e human bmp2 30 UTR and an alignment of miR-140-5p with the wild-type (WT) and
d nucleotides are highlighted in red and underlined. (D) Luciferase reporter assay.
p2 30 UTR or the mutated bmp2 30 UTR and 50 nM of a negative control mimic (NC
periments.
Fig. 3. Inhibition of miR-140-5p alters the expression of BMP2 and BMP signaling molecules in hMSCs. (A) hMSCs were transfected with LNA miR-140-5p inhibitor (50 nM)
and RNA was collected 48 h after transfection. qRT-PCR analysis was used to examine the expression of miR-140-5p (n = 6) (⁄P = 0.0005). NC, negative control. (B) mRNAs
from hMSCs transfected with miR-140-5p inhibitor were analyzed by qRT-PCR (n = 4) (⁄P = 0.0085). (C) (Left) Western blot of BMP2 protein in LNA-NC and LNA-miR-140-5p
transfected hMSCs. (Right) Quantiﬁcation of immunoblotted BMP2. To compare replicates, samples were normalized by setting the LNA-negative control (LNA-NC) to a value
of 1. Error bars denote the standard error of the mean of 3 experiments (⁄P < 0.05, Student’s t-test). (D) qRT-PCR analysis of BMP signaling components. The error bar denotes
the standard error of the mean of at least 5 experiments (⁄P < 0.05; ⁄⁄P < 0.001). (E) Western blot analysis of phospho-SMAD1/5, SMAD5 and BMPR2. hMSCs were transfected
with either LNA-NC or LNA-miR-140-5p for 24 h, then treated with or without BMP2 (100 ng/ml).
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way were next monitored by comparing the transcript levels of key
molecules in this pathway. Interestingly, the expression of BMPR2,
BMPR1B and SMAD5 signiﬁcantly increased when miR-140-5p
expression was blocked (Fig. 3D). More importantly, the levels of
SMAD5, phospho-SMAD1/5 and BMPR2 were enhanced upon
miR-140-5p inhibition, and the increases became more signiﬁcant
when hMSCs were treated with BMP2 (Fig. 3E and Supplementary
Fig. 2). In contrast, the introduction of the miR-140-5p mimic in
hMSCs led to downregulation of SMAD5, phospho-SMAD1/5 and
BMPR2 proteins in a BMP2-dependent manner (Supplementary
Fig. 3). Taken together, these results suggest that the inhibition
of miR-140-5p has a broader impact on BMP signaling in hMSCs.
3.5. Osteogenic markers are abnormally expressed in undifferentiated
hMSCs upon miR-140-5p inhibition
To further evaluate the functional activity of miR-140-5p, we
monitored the expression patterns of key regulators of osteogene-
sis after miR-140-5p inhibition under proliferation conditions.
After blocking miR-140-5p by LNA inhibitors, the expression levels
of osteogenic transcription factors such as RUNX2 and osteogenicmarkers including ALP, OCN, and OPN were reproducibly increased
under proliferation condition (Fig. 4A). Next, we aimed to deter-
mine the biological effects of miR-140-5p in osteoblast differenti-
ation by monitoring the expression of ALP. First, we conﬁrmed
that the level of miR-140-5p was signiﬁcantly reduced to more
than 69% in LNA-miR-140-5p transfected hMSCs during the osteo-
genic differentiation (data not shown). Following osteogenic
induction, we observed increased levels of ALP staining when
miR-140-5p was inhibited (Fig. 4B, top). In addition, ALP staining
was enhanced when hMSCs were treated with exogenous BMP2
after inhibiting miR-140-5p (Fig. 4B, bottom). The opposite effects
were observed in hMSCs overexpressing miR-140-5p (Supplemen-
tary Fig. 4). These results further support the idea that miR-140-5p
suppresses BMP2-mediated osteoblast differentiation.
Since the balance between osteogenic and adipogenic differen-
tiation is well-established in hMSCs and its misregulation is often
disrupted in various human diseases [25,26], we next examined
whether miR-140-5p inhibition would affect adipogenic lineage
commitment. Using real-time PCR analysis, we found that the
expression level of peroxisome proliferator-activated receptor
gamma (PPARc), a key transcription factor in adipogenesis, was
expressed similarly in both LNA-NC and LNA-miR-140-5p
Fig. 4. Key regulators of osteogenesis are misregulated upon miR-140-5p inhibition in hMSCs. (A) Real-time RT-PCR analysis of osteogenic differentiation markers. Error bars
denote the standard error of the mean of 3 experiments (⁄P < 0.05). (B) ALP staining at day 7 of osteogenic differentiation showed the increased ALP activity upon miR-140-5p
inhibition both in the presence (bottom) and absence (top) of BMP2 (100 ng/ml). (C) A model for the molecular switch controlling osteogenic lineage commitment by miR-
140-5p. miR-140-5p functions in undifferentiated hMSCs by suppressing osteogenic differentiation through BMP2 and the BMP signaling pathway. The inhibition of miR-140-
5p leads to the misregulation of osteogenic differentiation markers under proliferation state.
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esis markers of differentiation including fatty acid binding protein
4 (FABP4) and lipoprotein lipase (LPL) were not signiﬁcantly
affected by miR-140-5p inhibition (Supplementary Fig. 5). Hence,
we concluded that miR-140-5p has a broad inhibitory effect on
osteogenesis in undifferentiated hMSCs.
4. Discussion
The lineage commitments have to be tightly regulated during
stem cell maintenance to achieve the ﬁne balance between prolif-
eration and differentiation. Several studies have demonstrated that
miRNAs are critical regulators of osteoblast differentiation [27].
We have here identiﬁed miR-140-5p as an enriched miRNA in
undifferentiated hMSCs which negatively regulates an osteogenic
lineage commitment. We also demonstrated that the expression
levels of miR-140-5p were dynamically regulated during osteo-
genic differentiation. Consistent with our ﬁndings, recent miRNA
proﬁling studies had demonstrated that miR-140-5p was one of
the miRNAs downregulated in various differentiated cell types
compared with undifferentiated hMSCs [14,15], but its functional
roles had not been investigated in these earlier reports.
Interestingly, cluster analysis of these three groups of hMSCs
indicated that ADSCs and BMSCs have more similar miRNA proﬁles
to each other than to UCSCs, reﬂecting the differences in their ori-
gins. Previous studies have demonstrated that even though hMSCs
from different tissue sources have a similar morphology and
express common surface markers, they show different characteris-
tics in terms of differentiation, proliferation, and motility capabil-
ity [15,28]. The differences in the miRNA expression proﬁles of
these cell types might underlie these functional diversities.miR-
140-5p has long been established as a cartilage-speciﬁc miRNA
[29] that functions in cartilage homeostasis and osteoarthritis
[30,31]. Broader roles for miR-140-5p have only recently been
reported. For example, miR-140-5p was previously identiﬁed as a
potential tumor suppressor in many cancers [32,33] and a circulat-
ing miRNA showing a strong correlation with numerous diseases
[34–36]. A recent study has also demonstrated that miR-140-5pis involved in testis differentiation in mice [37]. Thus, evidence
exists for a diversity of biological functions for miR-140-5p.
In addition to demonstrating the direct repression of BMP2 by
miR-140-5p, as previously described [24], we identiﬁed its func-
tion by inhibiting miR-140-5p expression in hMSCs. We found that
miR-140-5p inhibition affected the expression of a subset of BMP
signaling components, which are essential for osteoblastic differ-
entiation and bone formation [38]. In addition, we showed that
the blocking of miR-140-5p in hMSCs causes an abnormal induc-
tion of key regulators of osteogensis in undifferentiated hMSCs.
The observed increases in the expression levels upon the miR-
140-5p inhibition were not likely due to the direct binding of
miR-140-5p to the 30 UTR regions of the BMP signaling components
and osteoblast differentiation markers. An extensive bioinformatic
analysis with less stringent miRNA ﬁlters using TargestScan 6.0
and IPA softwares revealed the lack of direct binding sites for
miR-140-5p in their 30 UTR regions except for bmp2 (data not
shown). We still note the possibility that miR-140-5p regulates
its targets through the region outside of the 30 UTR. Nevertheless,
the increases in their expression upon miR-140-5p inhibition seem
to be an indirect consequence of BMP2 induction, which has been
observed previously in other systems [8,39]. We therefore suggest
that miR-140-5p is a general ‘‘stemness’’ miRNA candidate in
undifferentiated hMSCs that modulates the decision of these cells
for osteogenic differentiation (Fig. 4C). It remains a challenge to
identify the potential roles of miR-140-5p and other likely miRNAs
in various lineage commitments that might have a meaningful
impact on clinical applications of hMSCs.
5. Accession number
The miRNA proﬁling data are available at the Gene Expression
Omnibus (GEO) database with accession number GSE57266.
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